Menopausal transition: risks and their prevention

2020 ◽  
pp. 26-30
Author(s):  
L. V. Tkachenko ◽  
N. I. Sviridova
Keyword(s):  
Hormone Therapy ◽  
Sex Hormones ◽  
Crucial Role ◽  
Dosage Forms ◽  
Estrogen Deficiency ◽  
Menopausal Hormone Therapy ◽  
Menopausal Transition ◽  
Cancer Risks ◽  
Compensatory Reactions ◽  
Urogenital Symptoms

The period of the menopausal transition from 40–45 years to menopause – is the crucial period of a woman’s life, in which, against the background of increasing estrogen deficiency, in addition to the appearance of vasomotor, psychological, and urogenital symptoms, complications and exacerbations of accumulated extagenital diseases occur. The loss of the natural balance of sex hormones leads to hyperplastic processes in hormone-dependent tissues, which leads to cancer risks. In solving this problem, menopausal hormone therapy (MHT) can play a crucial role, but this will become possible if, when choosing drugs for MHT, preference will be given to the safest dosage forms that provide the whole spectrum of compensatory reactions, including the prevention of dramatic situations of this age.

Menopausal hormone therapy and cancer risks of reproductive system. Literature review

2019 ◽  
Vol 1 (1) ◽  
pp. 42-50
Author(s):  
Ya. Z. Zaydieva
Keyword(s):  
Literature Review ◽  
Hormone Therapy ◽  
Hormonal Therapy ◽  
Reproductive System ◽  
Menopausal Hormone Therapy ◽  
Menopausal Transition ◽  
Continuous Mode ◽  
Cancer Risks ◽  
Oncological Diseases

Data on risks of development of oncological diseases of bodies of reproductive system in women during menopausal transition and in a postmenopause are submitted at treatment of menopausal frustration by the preparations intended for menopausal hormonal therapy, the containing various doses of estrogen and progestogen used in the cyclic or continuous mode.

scholarly journals Update on Menopausal Hormone Therapy for Fracture Prevention

2019 ◽  
Vol 17 (6) ◽  
pp. 465-473 ◽  
Author(s):  
Jan J. Stepan ◽  
Hana Hruskova ◽  
Miloslav Kverka
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Bone Loss ◽  
Cancer Risk ◽  
Hormone Therapy ◽  
Estrogen Deficiency ◽  
Menopausal Hormone Therapy ◽  
Early Years ◽  
Positive Effects ◽  
Prevention Of Bone Loss

Abstract Purpose of Review The goal of the review is to assess the appropriateness of menopausal hormone therapy (MHT) for the primary prevention of bone loss in women at elevated risk in the early years after menopause. Recent Findings Estrogen alone or combined with progestin to protect the uterus from cancer significantly reduces the risk of osteoporosis-related fractures. MHT increases type 1 collagen production and osteoblast survival and maintains the equilibrium between bone resorption and bone formation by modulating osteoblast/osteocyte and T cell regulation of osteoclasts. Estrogens have positive effects on muscle and cartilage. Estrogen, but not antiresorptive therapies, can attenuate the inflammatory bone-microenvironment associated with estrogen deficiency. However, already on second year of administration, MHT is associated with excess breast cancer risk, increasing steadily with duration of use. Summary MHT should be considered in women with premature estrogen deficiency and increased risk of bone loss and osteoporotic fractures. However, MHT use for the prevention of bone loss is hindered by increase in breast cancer risk even in women younger than 60 years old or who are within 10 years of menopause onset.

scholarly journals Uterine fibroids in premenopausal women

2019 ◽  
pp. 123-128
Author(s):  
Yu. E. Dobrokhotova ◽  
I. Yu. Ilina
Keyword(s):  
Drug Treatment ◽  
Hormone Therapy ◽  
Uterine Fibroid ◽  
Conservative Therapy ◽  
Uterine Fibroids ◽  
Premenopausal Women ◽  
Incidence Rates ◽  
Estrogen Deficiency ◽  
Menopausal Hormone Therapy ◽  
Premenopausal Patients

Uterine fibroids are one of the commonest benign pelvic tumours with an estimated incidence of 20–40% in women during their reproductive years. Incidence rates for uterine fibroid diagnoses were highest in premenopausal age. The gynecologists are frequently faced with need for the administration of menopausal hormone therapy (MHT) in this group of patients with the onset of symptoms associated with estrogen deficiency; however, uterine fibroids represent a relative contraindication for the administration of MHT. In the present paper, we point out the need for conservative therapy of uterine fibroids in premenopausal patients to prepare for the administration of MHT. The paper reflects the efficacy of the drug treatment of uterine fibroids using antigestagens (gynestril).

Management of patients with uterine bleeding during menopausal hormone therapy

2021 ◽  
Author(s):  
А.З. Хашукоева ◽  
М.В. Бурденко ◽  
А.В. Оверко ◽  
Т.Е. Рыжова ◽  
М.С. Сафонина
Keyword(s):  
Life Expectancy ◽  
Hormone Therapy ◽  
Uterine Bleeding ◽  
Menopausal Hormone Therapy ◽  
Menopausal Transition ◽  
Therapeutic Effects ◽  
Climacteric Syndrome ◽  
Climacteric Symptoms ◽  
Long Life ◽  
Selection Of

Тенденции по увеличению продолжительности жизни, которые наблюдаются в последние десятилетия, напрямую затрагивают деятельность акушера-гинеколога ввиду того, что женщинам необходимо не только прожить долгую жизнь, но и снизить количество заболеваний, развитие которых нередко связано с наступлением периода менопаузального перехода и постменопаузы. Задача врачей – помочь пациенткам максимально мягко войти в период постменопаузы, минимизировав проявления климактерического синдрома. В настоящее время наиболее эффективным методом терапии ранних климактерических симптомов является менопаузальная гормональная терапия. В статье рассмотрены современные подходы к проведению менопаузальной гормональной терапии при возникновении менопаузальных расстройств, подходы к подбору менопаузальной гормональной терапии с учетом особенностей каждой конкретной пациентки. Рассматриваются терапевтические эффекты и возможности менопаузальной гормональной терапии, проблемы ее приемлемости, а также ведение пациенток в постменопаузальном периоде с маточными кровотечениями. The trends in life expectancy that have been observed in recent decades directly affect the activities of an obstetrician-gynecologist due to the fact that women need not only to live a long life, but also to reduce the number of diseases, the development of which is often associated with the onset of the menopausal transition and postmenopause. The task of doctors is to help patients to enter the postmenopausal period as gently as possible, minimizing the manifestations of the climacteric syndrome. Currently, the most effective method of treating early climacteric symptoms is menopausal hormone therapy. The article discusses modern approaches to the conduct of menopausal hormone therapy in the event of menopausal disorders, approaches to the selection of menopausal hormone therapy, taking into account the characteristics of each individual patient. The therapeutic effects and possibilities of menopausal hormone therapy, the problems of its acceptability, as well as the management of postmenopausal patients with uterine bleeding are considered.

Clarifying breast cancer risks associated with menopausal hormone therapy

2006 ◽  
Vol 7 (11) ◽  
pp. 885-886 ◽  
Author(s):  
Montserrat Garcia-Closas ◽  
Mark E Sherman ◽  
Louise A Brinton
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Menopausal Hormone Therapy ◽  
Cancer Risks

Menopausal hormone therapy and uterine cancer: the acceptability of the tandem

GYNECOLOGY ◽  
2018 ◽  
Vol 20 (6) ◽  
pp. 42-47
Author(s):  
O V Yakushevskaya ◽  
S V Yureneva ◽  
A E Protasova ◽  
G N Khabas ◽  
M R Dumanovskaya
Keyword(s):  
Hormone Therapy ◽  
Uterine Cancer ◽  
Menopausal Hormone Therapy ◽  
Medical Rehabilitation ◽  
Cytostatic Treatment ◽  
Systematic Analysis ◽  
Strict Adherence ◽  
Patient Profile ◽  
The Past

The aim of the work is to conduct a systematic analysis of the available research results on the possibility of using menopausal hormone therapy (MHT) in patients who successfully completed the treatment of endometrial cancer (EC). Materials and methods. The review includes data from foreign articles published in PubMed and Medline, and domestic works published on elibrary.ru over the past 40 years. Results. The results obtained allow us to consider MHT as an independent method of medical rehabilitation for women who have undergone EC. A clear patient profile should be established, allowing the use of this method, with strict adherence to health monitoring. Conclusion Patients who have successfully completed the treatment of EC require the creation of special rehabilitation conditions in the interests of maintaining health and quality of life and should be under the close attention of the doctor. Argumented approaches to the appointment of MHT in such patients will avoid complications associated with estrogen deficiency after surgery, radiation with or without systemic (cytostatic) treatment methods.

Sign in / Sign up

Export Citation Format

Share Document